38 Participants Needed

Lomecel-B Injection for Hypoplastic Left Heart Syndrome

(ELPIS II Trial)

Recruiting at 7 trial locations
KV
SS
SB
KM
Overseen ByKiran Mansoor, MBBS
Age: < 18
Sex: Any
Trial Phase: Phase 2
Sponsor: Longeveron Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The purpose of this study is to test whether Lomecel-B™ works in treating patients with hypoplastic left heart syndrome (HLHS) and to gather additional information about the safety of Lomecel-B. Lomecel-B contains human mesenchymal stem cells (MSCs) as the active ingredient. MSCs are special cells in the body that are able to change into other types of cells, such as heart, blood, and muscle cells. MSCs are found in various tissues of the body, such as the bone marrow, which is the spongy tissue inside of your bones. Lomecel-B uses MSCs from bone marrow of unrelated young healthy donors. These are called "allogeneic", and do not require donor matching to the patient.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

What data supports the effectiveness of the treatment Lomecel-B Injection for Hypoplastic Left Heart Syndrome?

Research suggests that mesenchymal stem cells, like those in Lomecel-B, may help improve heart function in conditions similar to hypoplastic left heart syndrome by supporting the heart's ability to pump blood. Studies in animals and early human trials have shown potential benefits in heart function, which is promising for future treatment options.12345

Is Lomecel-B Injection safe for humans?

The ELPIS trial is testing the safety of Lomecel-B (mesenchymal stem cells) in children with hypoplastic left heart syndrome by monitoring for major heart-related issues. This study aims to ensure the treatment is safe before moving to further testing.14678

How is the Lomecel-B treatment different from other treatments for hypoplastic left heart syndrome?

Lomecel-B is unique because it uses mesenchymal stem cells (special cells that can develop into different types of cells) to potentially improve heart function in children with hypoplastic left heart syndrome, aiming to enhance the right ventricle's performance and possibly delay or avoid heart transplantation, unlike traditional surgical methods.145910

Research Team

SB

Stu Berger, MD

Principal Investigator

Ann & Robert H Lurie Children's Hospital of Chicago

Eligibility Criteria

This trial is for patients with Hypoplastic Left Heart Syndrome (HLHS) who are scheduled for Stage II heart surgery. It's not suitable for those unwilling to follow the study plan, with pacemakers, needing additional heart surgeries at the time of Stage II operation, or infected with HIV/HBV/HCV. People allergic to DMSO can't join.

Inclusion Criteria

I have HLHS and need a Stage II heart surgery.

Exclusion Criteria

I am having the Norwood procedure but do not have hypoplastic left heart syndrome.
I have a pacemaker or will get one before my Stage II treatment.
I need a device to help my heart pump blood right before my second heart surgery.
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Lomecel-B injections during their Stage II palliation

30 days
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 months
Regular visits (in-person and virtual)

Treatment Details

Interventions

  • Lomecel-B
Trial OverviewThe trial tests Lomecel-B™, which contains human mesenchymal stem cells from bone marrow donors. These cells may transform into heart and other types of cells and could help treat HLHS by repairing heart tissue.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Lomecel B GroupExperimental Treatment1 Intervention
Participants randomized to receive Lomecel-B injections during their Stage II palliation.
Group II: No Study Intervention Control GroupActive Control1 Intervention
Participants randomized to receive no study intervention during their Stage II palliation.

Lomecel-B is already approved in United States for the following indications:

🇺🇸
Approved in United States as Lomecel-B for:
  • None approved; under investigation for Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s Disease, and Aging-related Frailty

Find a Clinic Near You

Who Is Running the Clinical Trial?

Longeveron Inc.

Lead Sponsor

Trials
10
Recruited
480+

Ann & Robert H Lurie Children's Hospital of Chicago

Collaborator

Trials
275
Recruited
5,182,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

The University of Texas Health Science Center, Houston

Collaborator

Trials
974
Recruited
361,000+

Findings from Research

The ELPIS trial is investigating the safety and feasibility of injecting bone marrow-derived mesenchymal stem cells (MSCs) in 10 children with hypoplastic left heart syndrome (HLHS) to improve right ventricular function, with a focus on monitoring for major adverse cardiac events.
If the initial phase is successful, a larger phase IIb trial will compare MSC injection to standard surgical care in 20 patients, aiming to assess improvements in cardiac function and reduce the need for transplantation.
Study design and rationale for ELPIS: A phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome.Kaushal, S., Wehman, B., Pietris, N., et al.[2018]
Regenerative medicine approaches for treating hypoplastic left heart syndrome (HLHS) offer a promising alternative to current palliative care methods, potentially leading to curative treatments.
Despite the potential, significant challenges remain in translating these innovative strategies into clinical practice, necessitating further scientific and technological advancements.
The Potential Role of Regenerative Medicine on the Future Management of Hypoplastic Left Heart Syndrome.Kelly, JM., Anderson, C., Breuer, CK.[2023]
In a phase I trial involving 14 patients with ischemic heart disease, the direct injection of autologous bone marrow stromal cells (BMSCs) into the heart was found to be safe and technically feasible when combined with surgical revascularization procedures like TMR or CABG.
At 1 year post-treatment, patients showed improved cardiac function in the areas treated with BMSCs and reported enhanced quality of life, including significant reductions in angina symptoms.
Intramyocardial Bone Marrow Stem Cells in Patients Undergoing Cardiac Surgical Revascularization.Chan, JL., Miller, JG., Zhou, Y., et al.[2021]

References

Study design and rationale for ELPIS: A phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome. [2018]
The Potential Role of Regenerative Medicine on the Future Management of Hypoplastic Left Heart Syndrome. [2023]
Intramyocardial Bone Marrow Stem Cells in Patients Undergoing Cardiac Surgical Revascularization. [2021]
Stem Cell Therapy for Hypoplastic Left Heart Syndrome: Mechanism, Clinical Application, and Future Directions. [2020]
Autologous bone marrow mesenchymal cell transplantation improves left ventricular function in a rabbit model of dilated cardiomyopathy. [2018]
Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD Study). [2022]
Establishment of NCHi009-A, an iPSC line from a patient with hypoplastic left heart syndrome (HLHS) carrying a heterozygous NOTCH1 mutation. [2023]
Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. [2015]
Characterization of an iPSC line NCHi006-A from a patient with hypoplastic left heart syndrome (HLHS). [2022]
[Hypoplastic left heart syndrome. Clinical evaluation of 40 patients]. [2016]